Indoco Remedies · NSE: INDOCO · BSE: 532612
Q1 FY23 results · Apr–Jun 2022
Indoco Remedies reported revenue from operations of ₹408.22 crore (up 5.6% from Q1 FY22) and net profit of ₹38.57 crore (down 2.7% from Q1 FY22) for Q1 FY23 (Apr–Jun 2022), on a consolidated basis.
| Item | Q1 FY23 | Q1 FY22 | YoY | Q4 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 408.22 | 386.75 | +5.6% | 409.13 | −0.2% |
| Other income | 1.13 | 0.86 | +31.4% | 0.30 | +276.7% |
| Total income | 409.35 | 387.61 | +5.6% | 409.43 | −0.0% |
| Profit before tax | 48.35 | 61.29 | −21.1% | 59.75 | −19.1% |
| Net profit for the period | 38.57 | 39.66 | −2.7% | 40.45 | −4.6% |
| Attributable to shareholders of the company | (0.98) | 39.66 | Turned loss | 40.45 | Turned loss |
| EPS, basic (₹) | 4.19 | 4.30 | −2.6% | 4.39 | −4.6% |
| Net margin (%) | 9.4 | 10.3 | 9.9 |
| Item | Q1 FY23 | Q1 FY22 | YoY | Q4 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 407.90 | 386.49 | +5.5% | 408.88 | −0.2% |
| Other income | 1.13 | 0.86 | +31.4% | 0.29 | +289.7% |
| Total income | 409.03 | 387.35 | +5.6% | 409.17 | −0.0% |
| Profit before tax | 48.20 | 61.21 | −21.3% | 59.68 | −19.2% |
| Net profit for the period | 38.47 | 39.61 | −2.9% | 40.37 | −4.7% |
| EPS, basic (₹) | 4.17 | 4.30 | −3.0% | 4.38 | −4.8% |
| Net margin (%) | 9.4 | 10.2 | 9.9 |
Consolidated
- Filed with BSE
- 10 Aug 2022, 09:56 IST
- Board meeting
- 09 Aug 2022
- Period
- 01 Apr 2022 to 30 Jun 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 10 Aug 2022, 09:56 IST
- Board meeting
- 09 Aug 2022
- Period
- 01 Apr 2022 to 30 Jun 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE